Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Purchased by Blair William & Co. IL

Blair William & Co. IL raised its position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 11.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 98,466 shares of the company’s stock after buying an additional 10,000 shares during the quarter. Blair William & Co. IL owned about 0.35% of Vistagen Therapeutics worth $290,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in shares of Vistagen Therapeutics by 4,826,425.0% in the fourth quarter. JPMorgan Chase & Co. now owns 772,244 shares of the company’s stock valued at $2,278,000 after buying an additional 772,228 shares in the last quarter. Prosperity Wealth Management Inc. acquired a new position in shares of Vistagen Therapeutics during the 4th quarter worth $86,000. HighTower Advisors LLC acquired a new position in shares of Vistagen Therapeutics during the 3rd quarter worth $64,000. Jane Street Group LLC purchased a new position in shares of Vistagen Therapeutics in the 3rd quarter valued at about $59,000. Finally, R Squared Ltd acquired a new stake in shares of Vistagen Therapeutics in the fourth quarter valued at about $25,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

Vistagen Therapeutics Trading Up 3.1 %

Shares of VTGN opened at $2.35 on Friday. Vistagen Therapeutics, Inc. has a twelve month low of $2.15 and a twelve month high of $5.41. The firm has a market capitalization of $67.83 million, a P/E ratio of -1.59 and a beta of 0.56. The firm’s 50-day moving average is $2.73 and its two-hundred day moving average is $2.82.

Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings results on Thursday, February 13th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02. The business had revenue of $230 billion for the quarter, compared to analysts’ expectations of $0.18 million. Vistagen Therapeutics had a negative return on equity of 48.12% and a negative net margin of 6,777.08%. Analysts predict that Vistagen Therapeutics, Inc. will post -1.77 EPS for the current year.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.